OBI Pharma Announces Phase 1/2 Study Initiation for OBI-992, a TROP2-Targeted Antibody-Drug Conjugat
资讯
2024-06-12
Clinical trial to evaluate the safety and efficacy of OBI-992 in advanced solid tumors.
TAIPEI, Taiwan, June 12, 2024 (GLOBE NEWSWIRE) - OBI Pharma, a clinical-stage oncology company (4174.TWO), toda...